Sentences with phrase «vaccine technology in»

Phillips and Schultz, of the Scripps Research Institute and University of Wisconsin, respectively, reviewed the state of canine and feline vaccine technology in Current Veterinary Therapy XI.

Recombinant vaccines represent the very cutting edge of vaccine technology in both veterinary and human medicine.

In April 2017, Moderna published human data for its mRNA vaccine technology in Molecular Therapy, which showed that its first prophylactic vaccine candidate, mRNA - 1440 — an mRNA prophylactic vaccine against avian H10N8 influenza — induced high levels of immunogenicity and was safe and well tolerated.

Because the H10N8 and H7N9 strains are not circulating in the general population where the trials are taking place (the U.S. and Germany), Moderna is able to study the efficacy of its vaccine technology in naïve patient populations.

«This is a straightforward study of the use of two established vaccine technologies in an attempt to design and test new Zika vaccines.

Not exact matches

Joy: Yeah, but the point is we have the technology now to sequence and manufacture vaccines fairly quickly; and ideally they wouldn't be grown in eggs or whatever, right; because what if it starts as a virus in chickens or something, and we're screwed.

Evans, for his part, says he «was far more interested in advancing the technology» than in developing a vaccine.

To create a new dengue virus vaccine, Stefan Metz, Shaomin Tian in the laboratories of Aravinda de Silva, Chris Luft and Joe DeSimone at the University of Carolina, Chapel Hill, USA designed nanoparticles of various shapes and sizes using Particle Replication in Non-wetting Template (PRINT) technology.

Phase II trials for that vaccine candidate are set to begin within the next two months, so it will not likely be available to combat the current swine flu outbreak, which could kill as many as 90,000 Americans and land up to 1.8 million in the hospital, according to the President's Council of Advisors on Science and Technology (PCAST).

Currently, most influenza vaccines in the United States are produced using chicken eggs, while a few are made in cell culture or by using recombinant DNA technologies.

of the world since it began nearly three years ago, and he suggests a way to prevent similar disputes in the future: Developed countries should provide technology transfer to help poor countries, allowing them to produce their own vaccines.

Examples include changing policies to encourage older adults to remain part of the workforce for longer (e.g., removing tax disincentives to work past retirement age), emphasising low - cost disease prevention and early detection rather than treatment (eg, reducing salt intake and increasing uptake of vaccines), making better use of technology (eg, mobile clinics for rural populations), and training health - care staff in the management of multiple chronic conditions.

BRUSSELS — CureVac, a company based in Tübingen, Germany, that develops RNA - based vaccines and therapies, has won a $ 2 million prize awarded by the European Commission to stimulate new vaccine technologies that might help the developing world.

5) Explore new vaccine technologies — Longer term, we need to evaluate new ways to vaccinate wild carnivores for distemper, in situations wherein use of an injectable vaccine is not feasible by hand or by dart.

Along with discussing the potential benefits — such as making seed vaccines in a day and producing biofuels — some debated whether Venter's part - artificial bacterium is a major advance or simply an extension of existing DNA technologies.

Jury member Penny Heaton, director of vaccine development at the Bill & Melinda Gates Foundation, said CureVac's RNA technology had «the potential for a large and positive impact on public health,» in a statement released by the company on 10 March.

In November 2012, the company also showed, along with scientists from the Friedrich Loeffler Institute, that the technology could lead to a new generation of flu vaccines.

The perspective concludes that modern vaccine technology and improved surveillance in developing countries ultimately can help us better prepare for emerging infectious disease threats.

With the completion of the first phase of the Human Genome Project in 2000, and the advent of sequencing technologies that can detect gene variations such as single nucleotide polymorphisms (SNPs), for the first time scientists have the tools in hand to find the key immune genes and genetic networks that play roles in vaccine response.

There are ongoing studies which focus on the discovery of molecular biomarkers of the VSV - ZEBOV vaccine in healthy individuals using omics - based technologies in combination with a systems biology approach,» says Ali Harandi.

The winners of the prize are Maged Al - Sherbiny from Egypt, for his research on vaccines and diagnostics against hepatitis C and schistosomiasis; plant scientist Felix Dapare Dakora from Tshwane University of Technology, Pretoria, in South Africa for his work on legumes and soil bacteria; and Rossana Arroyo of the Centre for Research and Advanced Studies of Mexico's National Polytechnic Institute, who studies trichomoniasis, a parasitic disease.

The ability to design new protein nanostructures could have useful implications in targeted delivery of drugs, in vaccine development and in plasmonics — manipulating electromagnetic signals to guide light diffraction for information technologies, energy production or other uses.

«This is an important demonstration of the possibilities opened up for immunotherapy by DMAb technology to direct in vivo production of antibodies of major relevance to human cancer,» said David B. Weiner, Ph.D., executive vice president of The Wistar Institute, director of The Wistar Institute Vaccine & Immunotherapy Center, W.W. Smith Charitable Trust Professor in Cancer Research, and senior author of the study.

The trial is sponsored by Global Health Innovative Technology Fund (Japan) and results of vaccine efficacy will be available in late 2018.

«It's a powerful vaccine technology that efficiently delivers vaccine components to the right cells in the right tissues.

Batista was one of a number of scientists involved in the study from the Ragon Institute, established in the Boston area by experts from Massachusetts General Hospital, Harvard University and the Massachusetts Institute of Technology, with the goal of working toward development of an effective vaccine against HIV / AIDS.

From that chat has arisen plans for the MSD Wellcome Trust Hilleman Laboratories — named after a vaccine scientist who worked at Merck — a non-profit research institute that it will act like a nimble biotech company with «dynamic decision - making» in the words of Ted Bianco, director of technology transfer at the Wellcome Trust.

IDMIT will contribute 1) To the development and validation of assays based on flow cytometry and mass cytometry for the evaluation of immune responses in humans and animal models; these tools will be particularly relevant for the identification of signatures of vaccine efficacy; 2) To the animal model platform, in particularly by providing access to NHP models and to new technologies for in vivo imaging infections and host responses; 3) To networking activities, in particular by organising a workshop on in vivo imaging.

These technologies are particularly powerful when looking for changes in concentrations of multiple targets under specific conditions, such as following a vaccine administration, infection, or a drug treatment.

Innovative imaging technologies to monitor responses to vaccines and infections in suitable models will provide information in characterisation of live vaccine (such as BCG) of its biodistribution and persistence.

The VFL was established by the World Health Organization in 2010, in order to allow the global vaccine community to gain open access to adjuvant technology and vaccine formulation expertise.

TRANSVAC will further accelerate vaccine development by developing and applying cutting - edge technologies to address critical issues in modern vaccine development and thereby increase the quality of services provided.

We share and transfer our knowledge and technologies to partners worldwide, providing opportunities for contract research and out - licensing of (in - house) developed vaccine technologies.

Finally, the HZI will help develop in vivo imaging technologies to characterize (i) vaccine biodistribution and persistence, and (ii) cellular and molecular changes at the injection site and in draining lymphoid tissues, helping to refine the use of animal models.

The HZI will provide expertise and technologies for adjuvants and the preclinical validation of vaccine technologies and candidates in murine systems.

The Pilot Bioproduction Facility at WRAIR manufactured the ZPIV vaccine being used in Phase 1 clinical studies, and the Army recently signed a cooperative research and development agreement to transfer the ZPIV technology to Sanofi Pasteur to explore larger scale manufacturing and advanced development.

The module «Assay Development and Validation» will provide an insight into «state of the art» applications of SPR - technology in the context of vaccine development.

April 7, 2018 - The University of Florida, along with partners in the United States and Japan, received a $ 3.2 million grant from the Global Health Innovative Technology Fund to continue the development of a new malaria vaccine.

The DNA vaccine technology has not been easy to get to work in humans.

Massachusetts Institute of Technology (MIT) researchers have discovered a new way to model malaria using stem cells in a petri dish, which will allow them to test potential antimalarial drugs and vaccines.

Much of the laboratory's efforts on developing a new preventative vaccine for rabies — a disease that retains a disastrous presence in places across the globe — have yielded useful technologies that the Ertl laboratory is applying to combating other viruses.

For his part, Shusteff noted that the malarial vaccine purification system technology had been sitting in mothballs for three to four years — and has been given new life through the IDF.

Next, the researchers wanted to see if their technology could tackle some of the worst - growing vaccine strains in history.

Scientific programs include: human genomic sequencing and analysis, synthetic genomics and exploration of new vaccines using this technology, and environmental and single cell genomics to explore the vast unseen world of microbes living in the human body, the ocean, soil and air.

He has also participated in technology transfer projects in Brazil and India, where a vaccine formulation center has been constructed to manufacture IDRI - developed adjuvant formulations for clinical trials to evaluate malaria, leishmania, and tuberculosis vaccines.

Although some of the most successful vaccines have been live attenuated forms (e.g. measles vaccine, oral polio vaccine), most modern vaccines are based on recombinant DNA technologies in some shape or form.

Using enhanced DNA technology, the lab has designed DNA vaccines that drive immune responses in prophylactic or therapeutic settings against Human Immunodeficiency Virus (HIV), Dengue (DV), Chikungunya virus (CHIKV), Middle Eastern Respiratory Syndrome (MERS) virus, and Zika Virus (ZV).

Assay optimisation and technology transfer for multi-site immuno - monitoring in vaccine trials.

Currently serving as a consultant for the international vaccine community, Michel De Wilde was among the first to use recombinant DNA technology in the industry and has contributed to the discovery and development of a number of vaccines.

Important reports from the Weiner lab include the first DNA vaccine studied for HIV as well as for cancer immune therapy of cutaneous T cell lymphoma, the early development of DNA encoded genetic adjuvants, including IL - 12, advances in gene optimization, and advances in electroporation technologies resulting in improved gene delivery.